Insmed, Inc. (INSM) Stock Rating Reaffirmed by Cowen and Company
Insmed, Inc. (NASDAQ:INSM)‘s stock had its “buy” rating reissued by Cowen and Company in a research note issued to investors on Friday. They presently have a $54.00 target price on the biopharmaceutical company’s stock. Cowen and Company’s price target would suggest a potential upside of 79.94% from the stock’s previous close.
A number of other equities analysts also recently issued reports on INSM. Robert W. Baird started coverage on Insmed in a research note on Monday, July 10th. They set an “outperform” rating and a $23.00 target price for the company. Zacks Investment Research downgraded Insmed from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. HC Wainwright restated a “buy” rating on shares of Insmed in a report on Wednesday, August 2nd. ValuEngine cut Insmed from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Finally, BidaskClub cut Insmed from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. Insmed presently has a consensus rating of “Buy” and a consensus price target of $34.50.
Shares of Insmed (NASDAQ INSM) traded up $2.80 during mid-day trading on Friday, hitting $30.01. The stock had a trading volume of 665,653 shares, compared to its average volume of 485,637.
Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09). analysts anticipate that Insmed will post -2.68 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Insmed, Inc. (INSM) Stock Rating Reaffirmed by Cowen and Company” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/03/insmed-inc-insm-stock-rating-reaffirmed-by-cowen-and-company.html.
In other Insmed news, Director Donald J. Hayden, Jr. sold 45,000 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $29.67, for a total transaction of $1,335,150.00. Following the sale, the director now owns 71,131 shares in the company, valued at approximately $2,110,456.77. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Melvin Md Sharoky sold 50,000 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $27.37, for a total value of $1,368,500.00. The disclosure for this sale can be found here. Corporate insiders own 4.03% of the company’s stock.
A number of large investors have recently made changes to their positions in INSM. SG Americas Securities LLC acquired a new stake in Insmed during the 2nd quarter valued at $129,000. BNP Paribas Arbitrage SA grew its holdings in Insmed by 666.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,498 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 6,520 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new stake in Insmed during the 2nd quarter valued at $187,000. Driehaus Capital Management LLC acquired a new stake in Insmed during the 1st quarter valued at $192,000. Finally, Virtu KCG Holdings LLC acquired a new stake in Insmed during the 2nd quarter valued at $201,000. Hedge funds and other institutional investors own 73.07% of the company’s stock.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.